Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A Traditional Chinese Medicine (TCM) herbal compound, Gailiang Shenzhu Guanxin Fang is primarily indicated for the treatment of coronary heart disease (CHD), including stable angina pectoris. Its therapeutic effects are rooted in TCM principles, aiming to invigorate qi, eliminate phlegm, and promote blood circulation. This multi-ingredient formulation is believed to improve microcirculation, reduce blood viscosity, and exert antioxidant properties, thereby alleviating symptoms and improving cardiac function in patients with CHD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gailiang Shenzhu Guanxin Fang.